Full text is available at the source.
Real-World Effects of Semaglutide and Tirzepatide Compared to Weight-Loss Surgery
Updated
Abstract
Of 44,025 patients, bariatric surgery was associated with greater weight loss at 1, 2, and 3 years compared to GLP-1 receptor agonists.
- Total weight loss (TWL) at 1 year post-surgery was 24.4% for sleeve gastrectomy and 29.8% for gastric bypass.
- In comparison, semaglutide achieved a TWL of 5.4% and tirzepatide reached 9.1% at 1 year.
- At 3 years, gastric bypass patients experienced a TWL of 28.4%, while semaglutide and tirzepatide reported 7.4% and 10.8%, respectively.
- With 1 year of continuous GLP-1 receptor agonist use, semaglutide and tirzepatide had TWL of 8.8% and 11.9% at 3 years.
- Bariatric surgery may provide significantly greater weight loss outcomes compared to injectable GLP-1 receptor agonists over a 3-year period.
Simplified
GLP-1 Therapies